FilingSEC EDGAR6-K
Chemomab Therapeutics Ltd. Enters into Amendment to Merger Agreement
· SEC accepted
StageAgreement
Filing content
The company entered into an amendment to its merger agreement to establish a formula-based exchange ratio, ensuring the combined company has 10 million shares outstanding post-merger.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…